CompletedNot applicableNCT00433407

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

Studying Malignant non-epithelial tumor of ovary

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jonsson Comprehensive Cancer Center
Principal Investigator
Mark D. Pegram, MD
Jonsson Comprehensive Cancer Center
Intervention
trastuzumab(biological)
Enrollment
12 enrolled
Eligibility
All sexes
Timeline
2005

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00433407 on ClinicalTrials.gov

Other trials for Malignant non-epithelial tumor of ovary

Additional recruiting or active studies for the same condition.

See all trials for Malignant non-epithelial tumor of ovary

← Back to all trials